HC Wainwright Reiterates Buy Rating for AngioDynamics (NASDAQ:ANGO)

AngioDynamics (NASDAQ:ANGO - Get Free Report)'s stock had its "buy" rating reaffirmed by equities researchers at HC Wainwright in a report released on Wednesday,Benzinga reports. They presently have a $16.00 target price on the medical instruments supplier's stock. HC Wainwright's price objective would suggest a potential upside of 87.57% from the stock's previous close. HC Wainwright also issued estimates for AngioDynamics' Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at $0.02 EPS and FY2026 earnings at ($0.30) EPS.

Separately, Canaccord Genuity Group set a $17.00 target price on AngioDynamics and gave the company a "buy" rating in a research report on Wednesday.

AngioDynamics Trading Down 2.4%

Shares of ANGO traded down $0.21 during midday trading on Wednesday, hitting $8.53. 186,515 shares of the company's stock traded hands, compared to its average volume of 657,489. AngioDynamics has a 1 year low of $5.83 and a 1 year high of $13.50. The firm's fifty day moving average is $9.88 and its 200-day moving average is $10.07. The stock has a market capitalization of $346.40 million, a price-to-earnings ratio of -10.28 and a beta of 0.60.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its earnings results on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.09. AngioDynamics had a negative return on equity of 3.20% and a negative net margin of 11.62%. The firm had revenue of $80.16 million for the quarter, compared to the consensus estimate of $74.26 million. During the same period in the prior year, the firm earned ($0.06) EPS. The firm's revenue was up 13.0% on a year-over-year basis. On average, equities research analysts anticipate that AngioDynamics will post -0.37 EPS for the current year.

Institutional Investors Weigh In On AngioDynamics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quinn Opportunity Partners LLC acquired a new stake in AngioDynamics during the 4th quarter worth about $92,000. ProShare Advisors LLC acquired a new stake in AngioDynamics during the 4th quarter worth about $100,000. Graham Capital Management L.P. acquired a new stake in AngioDynamics during the 4th quarter worth about $106,000. OneDigital Investment Advisors LLC boosted its stake in shares of AngioDynamics by 14.0% during the 4th quarter. OneDigital Investment Advisors LLC now owns 12,137 shares of the medical instruments supplier's stock worth $111,000 after acquiring an additional 1,490 shares in the last quarter. Finally, Cerity Partners LLC boosted its stake in shares of AngioDynamics by 22.0% during the 1st quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier's stock worth $121,000 after acquiring an additional 2,333 shares in the last quarter. 89.43% of the stock is owned by institutional investors and hedge funds.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.